The polymer drug delivery system was developed at the Massachusetts Institute of Technology and licensed to Nova in 1986
Executive Summary
Soon after Nova licensed the biodegradable polymer from MIT, the Baltimore firm signed a $10 mil. research/equity investment agreement with Celanese to pursue drug delivery systems ("The Pink Sheet" March 31, 1986, T&G-1). In the current trials, the biodegradable polymer will be used with the anti-cancer generic drug BCNU. After a brain tumor is removed, the polymer/BCNU will be implanted into the patient's brain, releasing high concentrations of the drug in an attempt to destroy any remaining cancer cells. Nova has worldwide exclusive rights to all pharmaceutical applications of the drug delivery technology.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth